Assistant Professor in the Division of Gastroenterology and Hepatology at the University of Michigan. Holds NIDDK K08 DK132312 and received the AASLD Foundation’s 2020 Clinical, Translational and Outcomes Research Award in Liver Disease. First author of the 2023 Gastroenterology study on PNPLA3 genotype, diabetes and incident cirrhosis in NAFLD.

Associate Professor of Medicine and consultant in the Division of Community Nephrology and Hypertension at Mayo Clinic in Rochester, Minnesota. Works on the epidemiology of kidney stones, including risk factors, recurrence prediction and urine metabolic profiles in stone formers, alongside acute kidney injury and the clustering and long‑term impact of electrolyte disorders.

Head of Division and Senior Consultant, Body Imaging, at National University Hospital, subspecialising in hepatobiliary and oncological imaging, and core faculty on the NUHS Diagnostic Radiology Residency Programme. First author of the 2026 Alimentary Pharmacology & Therapeutics systematic review calling for standardised imaging‑based morphological criteria for liver cirrhosis.

Senior Scientist at A*STAR’s Institute of Molecular & Cell Biology (IMCB). His research interests lie mainly at the intersection of chemistry and biology, where he seeks to incorporate new tools in tackling challenging and important biological problems. His work focuses on inventing optogenetic tools to dissect signalling pathways that are important for growth and metabolic sensing. Ong is also intrigued by how perturbations such as metabolites, light and oxidative stress could perturb cellular signalling.

Chairman of the Japanese Association of Rehabilitation Nutrition and chair of its clinical guidelines committee. Directs the Center for Sarcopenia and Malnutrition Research at Kumamoto Rehabilitation Hospital, established in 2020, and co‑authored Japan’s Guidelines for Nutritional Management of Sarcopenia and Frailty 2025 (Geriatrics & Gerontology International).

Consultant in the Department of Cardiology at the National University Heart Centre, Singapore, and Adjunct Assistant Professor at the NUS Yong Loo Lin School of Medicine. Works on cardiomyopathies, cardio‑neurology and the brain–heart interaction, and multi‑modality cardiac imaging across echocardiography, nuclear cardiology, CT and cardiovascular MRI.

Group Leader in Systems Immunology and Immune Engineering at A*STAR’s Singapore Immunology Network, appointed in December 2024. His laboratory uses single‑cell sequencing, spatial omics and transgenic models to work out how neutrophils are reprogrammed inside tumours and how mast cells drive keloid scarring, with the aim of finding pathways that can be targeted. Holds an NMRC Young Investigator Research Grant and an SRIS Joint Research Grant.

Professor of Cardiovascular Medicine and of Molecular Medicine at Wake Forest, where he holds the inaugural Fred M. Parrish Professorship of Cardiology and Molecular Medicine and directs the Center for Prevention of Cardiovascular Disease. Immediate‑Past President of the American Society for Preventive Cardiology and Chair‑elect of the AHA Council on Lipidology, Lipoprotein, Metabolism and Thrombosis. First author of “Preventive Cardiology as a Subspecialty of Cardiovascular Medicine” (Journal of the American College of Cardiology, 2019) and senior author of a review of apolipoproteins in vascular biology and atherosclerotic disease (Nature Reviews Cardiology, 2022).

Senior Consultant in Cardiology at the National Heart Centre Singapore and Clinical Assistant Professor at Duke‑NUS since 2022. First and corresponding author of PANES‑HF (Scientific Reports, 2024), which tested point‑of‑care AI‑enhanced echocardiography performed by a single novice operator to screen for heart failure, and first author of a SingHEART activity‑tracker analysis in JMIR mHealth and uHealth (2025).

Gastroenterologist and transplant hepatologist at Mayo Clinic in Jacksonville, Florida, previously Associate Professor of Medicine and Director of Clinical Research at the University of Arizona College of Medicine – Phoenix. Works on the epidemiology of steatotic liver disease, liver transplantation outcomes and disparities in liver care, and is corresponding author of the 2025 Clinical and Molecular Hepatology meta‑analysis of long‑term outcomes in lean versus non‑lean MASLD.

Medical Director of the Adult Liver Transplantation Programme at NUH and Adjunct Professor of Medicine at NUS, where he leads the Metabolic Liver Laboratory. Over 200 publications, named on the 2025 Stanford/Elsevier world top 2% most‑cited scientists list, and senior author of the 2023 Cell Metabolism global burden of metabolic disease study.

Assistant Professor of Metabolic, Nutrition and Microbiome Medicine at LKCMedicine, NTU, where his laboratory works on diet–microbe–host interactions and their effects on cardiometabolic and vascular disease. Took his MD and PhD at Kobe University, trained clinically in cardiology, and studied T‑cell immune responses in cardiovascular disease under Ken‑ichi Hirata. Completed postdoctoral training with Federico E. Rey at the University of Wisconsin–Madison on diet–microbiome interactions in cardiometabolic disease, and joined the LKCMedicine faculty in 2022.

Postdoctoral fellow at the National University of Singapore. First author of “Angptl4 integrates dietary and microbial signals to disrupt gut barrier function in MASH” (Nature Communications, 2026). Second author on “The LIDPAD Mouse Model Captures the Multisystem Interactions and Extrahepatic Complications in MASLD” (Advanced Science, 2024).

Holds the Personal Chair of Translational Liver Research at the University of Edinburgh and is an Honorary Consultant Hepatologist at the Royal Infirmary of Edinburgh. Senior author of SteatoSITE, the gene‑to‑outcome multimodal MASLD database built from 940 histologically characterised patients (Nature Medicine, 2023), and senior author of the phase 2 randomised trial of autologous macrophage therapy in cirrhosis (Nature Medicine, 2025).